Clinical usefulness of total length of Gleason pattern 4 on biopsy in men with Grade Group 2 prostate cancer Journal Article
| Authors: | Dean, L. W.; Assel, M.; Sjoberg, D. D.; Vickers, A. J.; Al-Ahmadie, H. A.; Chen, Y. B.; Gopalan, A.; Sirintrapun, S. J.; Tickoo, S. K.; Eastham, J. A.; Scardino, P. T.; Reuter, V. E.; Ehdaie, B.; Fine, S. W. |
| Article Title: | Clinical usefulness of total length of Gleason pattern 4 on biopsy in men with Grade Group 2 prostate cancer |
| Abstract: | PURPOSE: To our knowledge the ideal methodology of quantifying secondary Gleason pattern 4 in men with Grade Group 2/Gleason score 3 + 4 = 7 on biopsy remains unknown. We compared various methods of Gleason pattern 4 quantification and evaluated associations with adverse pathology findings at radical prostatectomy. MATERIALS AND METHODS: A total of 457 men with Grade Group 2 prostate cancer on biopsy subsequently underwent radical prostatectomy at our institution. Only patients with 12 or more reviewed cores were included in analysis. We evaluated 3 methods of quantifying Gleason pattern 4, including the maximum percent of Gleason pattern 4 in any single core, the overall percent of Gleason pattern 4 (Gleason pattern 4 mm/total cancer mm) and the total length of Gleason pattern 4 in mm across all cores. Adverse pathology features at radical prostatectomy were defined as Gleason score 4 + 3 = 7 or greater (Grade Group 3 or greater), and any extraprostatic extension, seminal vesical invasion and/or lymph node metastasis. A training/test set approach and multivariable logistic regression were used to determine whether Gleason pattern 4 quantification methods could aid in predicting adverse pathology. RESULTS: On multivariable analysis all Gleason pattern 4 quantification methods were significantly associated with an increased risk of adverse pathology (p <0.0001) and an increased AUC beyond the base model. The largest AUC increase was 0.044 for the total length of Gleason pattern 4 (AUC 0.728, 95% CI 0.663-0.793). Decision curve analysis demonstrated an increased clinical net benefit with the addition of Gleason pattern 4 quantification to the base model. The total length of Gleason pattern 4 clearly provided the largest net benefit. CONCLUSIONS: Our findings support the inclusion of Gleason pattern 4 quantification in the pathology reports and risk prediction models of patients with Grade Group 2/Gleason score 3 + 4 = 7 prostate cancer. The total length of Gleason pattern 4 across all cores provided the strongest benefit to predict adverse pathology features. |
| Journal Title: | Journal of Urology |
| Volume: | 201 |
| Issue: | 1 |
| ISSN: | 0022-5347 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2019-01-01 |
| Start Page: | 77 |
| End Page: | 82 |
| Language: | English |
| DOI: | 10.1016/j.juro.2018.07.062 |
| PUBMED: | 30076908 |
| PROVIDER: | scopus |
| PMCID: | PMC6786261 |
| DOI/URL: | |
| Notes: | Export Date: 1 February 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work